European Psychiatry
March 1, 2023
Saundarai Bhanot, Michelle Cq Lin, S. Bains et al.
3 citations
Introduction Psilocybin is a naturally occurring psychedelic compound whose effects have been seen in studies for treatment of depression, anxiety and pain management. Given its structural similarities to 5-hydroxytryptamine, a monoamine controlling brain modulation of pain input, preliminary studies sought to test serotonergic interactions of psilocybin with headaches. Objectives Explore...
Frontiers in Pharmacology
February 16, 2023
Yahong Chen, Junhong Liu, Yishan Yao et al.
19 citations
Psychedelics alter consciousness and may have potential for drug development. As psychedelics are likely therapeutically active, it is important to study their effects and mechanisms using preclinical models. Here, we examined the effects of phenylalkylamine and indoleamine psychedelics on locomotor activity and exploratory behaviour using the mouse Behavioural Pattern Monitor (BPM). DOM,...
PsyArXiv
February 1, 2023
Sonny Mattek
preprint
Virtual reality (VR) is an emerging tool that has been shown to induce experiences similar to psychedelics. In this report, we measure brain activity using electroencephalography (EEG) before and after a novel VR experience. This Inner State VR experience was designed as a drugless psychedelic journey that mimicks a microdosing experience, to create the opportunity of participating in a...
Neuropharmacology
January 21, 2023
Edward M. Sellers, Myroslava K. Romach
21 citations
The substantial challenges facing high and low dose psychedelic drug development to achieve regulatory approval have been documented in the scientific literature. These limitations have not deterred drug developers and social media from repeatedly misleading patients, the public and health professionals. Developing "micro doses" of psychedelics overcomes many of the scientific and regulatory...
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal
January 5, 2023
Kaden Venugopal, Nefissa Bedri
5 citations
Introduction: Psilocybin (the active compound found in “magic mushrooms”) has been an area of recent focus in the academic and psychiatric community on account of its potential in treating a spectrum of substance use and concurrent disorders (SUCDs). This paper posits a literature review of the current research pertaining to psilocybin in treating alcohol use disorder (AUD) through a form of...
Molecular Psychiatry
2023
Gilly Wolf, Sandeep Singh, Karin Blakolmer et al.
Schizophrenia is a widespread psychiatric disorder that affects 0.5-1.0% of the world's population and induces significant, long-term disability that exacts high personal and societal cost. Negative symptoms, which respond poorly to available antipsychotic drugs, are the primary cause of this disability. Association of negative symptoms with cortical atrophy and cell loss is widely reported....
The Transmitter
2023
Peter Hess
Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.
Frontiers in Pain Research
2023
Daniella Batievsky, Michelle Weiner, Shari B Kaplan et al.
8 citations
Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature. This paper reports the findings of an observational preliminary study that explored the efficacy of ketamine-assisted psychotherapy (KAPT) for chronic pain/major...
Neuropsychopharmacology
2023
Abigail E. Calder, Gregor Hasler
303 citations
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly, clinical improvements can last for months or years after treatment. It has been theorized that these long-term improvements arise because psychedelics rapidly and lastingly stimulate neuroplasticity. The focus of this review is...
Journal of Psychoactive Drugs
2023
Daniel J. Kruger, Nicolas G. Glynos, Christopher W Fields et al.
10 citations
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use of and harm reduction practices for psychedelics in the naturalistic use landscape. The current study piloted an assessment instrument with questions on legal status, therapeutic potential, and side effects of psychedelics among people reporting...